Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients

Inclusion Criteria: 1. Histopathology / cytology diagnosed as peripheral T cell lymphoma (PTCL) according to WHO 2016 classification criteria（NK/T cell lymphoma and ALK positive anaplastic large cell lymphoma excluded）including:Peripheral T-cell lymphoma, NOS，Angioimmunoblastic T-cell lymphoma，Anaplastic large-cell lymphoma, ALK negative，Enteropathy-associated T-cell lymphoma，Hepatosplenic T-cell lymphoma，Subcutaneous panniculitis T-cell lymphoma，Mycosis fungoides，Other T-cell lymphoma that investigators consider to be appropriate to be enrolled; 2. Patients have received CHOPE regimen for 2 cycles therapy and achieve PR or SD; 3. Patients should have at least one evaluable foci ( lymph nodes with diameter≥1.5cm, or evaluable skin foci); 4. Age 18-70 years, male or female; 5. ECOG performance status 0-2; 6. Absolute neutrophil count ≥1.5×109/L, platelet ≥75×109/L, Hb ≥ 90g/L; 7. ALT and serum creatinine \<1.5 times of normal maximum; 8. Life expectancy no less than 3 months; 9. Willing to sign the Informed Consent Form. Exclusion Criteria: 1. NK/T cell lymphoma or ALK positive anaplastic large cell lymphoma; 2. Female patients in lactation or pregnancy, Childbearing female or male patients unwilling to take contraceptive measures; 3. QTc elongation with clinical significance ( male\> 450ms, female\> 470ms), ventricular tachycardia, atrial fibrillation, cardiac conducting blockage, myocardial infarction within 1 year, congestive heart failure, symptomatic coronary heart disease that requires treatment; 4. Patients have undergone organ transplantation; 5. Patients received symptomatic treatment for bone marrow toxicity within 7 days prior to enrollment; 6. Patients with active hemorrhage; 7. Patients with or with history of thrombosis, embolism, cerebral hemorrhage, or cerebral infarction; 8. Patients with active infection or continuous fever within 14 days prior to enrollment; 9. Had major organ surgery within 6 weeks prior to enrollment; 10. Impaired liver function ( Total bilirubin \> 1.5 times of normal maximum, ALT/AST\> 2.5 times of normal maximum, for patients with infiltrative liver disease ALT/AST\> 5 times of normal maximum), impaired renal function (serum creatinine\> 1.5 times of normal maximum); 11. Patients with mental disorders or those do not have the ability to consent; 12. Patients with drug abuse, long term alcoholism that may impact the results of the trial; 13. Patients with invasion of central nervous system ; 14. Non-appropriate patients for the trial according to the judgment of the investigators.